Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281008 · ClinicalTrials.gov registry record · Phase 2
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
A Phase 2 study of Hypercholesterolemia, Familial, sponsored by Kastle Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 8
- Study locations
NCT00281008: Completed Phase 2 study of Hypercholesterolemia, Familial, sponsored by Kastle Therapeutics.
NCT00281008 is a Phase 2 study of Hypercholesterolemia, Familial that has completed, run by Kastle Therapeutics. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00281008, a Phase 2 study of Hypercholesterolemia, Familial, has completed, sponsored by Kastle Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 8
- Study locations
Study Summary
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
Conditions Studied
Interventions
- DRUG ISIS 301012 or Placebo
Study Locations (8)
Maine
- - Auburn
- - Scarborough
Illinois
- - Chicago
New York
- - New York
North Carolina
- - Winston-Salem
Ohio
- - Cincinnati
Texas
- - Houston
Other
- - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00281008 record still lists
NCT00281008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Hypercholesterolemia, Familial appearing as the primary indexed condition, and to 1 intervention - of which ISIS 301012 or Placebo is the first listed.
NCT00281008 lists 8 locations in 7 states (Maine, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT00281008 about?
NCT00281008 is a clinical study titled "Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy". The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
What is the current status of trial NCT00281008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2006-02. Estimated completion is 2007-12.
What conditions does trial NCT00281008 study?
This clinical trial studies the following conditions: Hypercholesterolemia, Familial.
What interventions are being tested in trial NCT00281008?
The interventions under investigation include: ISIS 301012 or Placebo (DRUG).
Who is sponsoring clinical trial NCT00281008?
This trial is sponsored by Kastle Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00281008 being conducted?
This trial has 8 study locations across Illinois, Maine, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia, Familial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00281008's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia